TTY Biopharm (4105.TWO) Earnings Analysis
TTY Biopharm (4105.TWO) next reports earnings on 2026-08-06, consensus EPS 1.57 TWD. Last quarter (2026-03-09) it missed with EPS 1.22 TWD vs 1.72 TWD est (-29.1%). It has beaten estimates in 0/1 recent quarters (0%). Trailing P/E 11.78.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 4105.TWO next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | 1.57 TWD |
| Revenue estimate | 1.68B |
4105.TWO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-09 | 1.22 TWD | 1.72 TWD | -29.1% | Miss |
Beat rate: 0/1 (0%) over reported quarters with consensus data.
4105.TWO valuation and analyst view
| Trailing P/E | 11.78 |
|---|---|
| Trailing EPS | 6.275 TWD |
| Price / book | 3.02 |
| Dividend yield | 5.91% |
| Market cap | 19.15B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is TTY Biopharm (4105.TWO)'s next earnings date?
TTY Biopharm is next scheduled to report on 2026-08-06, with a consensus EPS estimate of 1.57 TWD and revenue estimate of 1.68B.
Did 4105.TWO beat earnings last quarter?
In its 2026-03-09 report, 4105.TWO posted EPS of 1.22 TWD versus a 1.72 TWD estimate — a miss of 29.1%.
What is 4105.TWO's earnings track record?
Over the last 1 reported quarters with consensus data, 4105.TWO beat estimates 0 times (0%).
What is 4105.TWO's current P/E ratio and EPS?
4105.TWO trades at a trailing P/E of 11.78 on trailing EPS of 6.275267965918655 TWD.
What do analysts rate 4105.TWO?
4105.TWO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.